1. Introduction {#sec1}
===============

Hepatotoxicity is a common side effect of chemotherapy \[[@B1]\]. Prevalence of hepatotoxicity ranges from 33 to 65.6% among patients with cancer \[[@B2], [@B3]\], and up to 30% of patients have the third or fourth degree hepatotoxicity \[[@B4]\]. Although 90% of patients resumed normal liver function after stopping use of hepatotoxic drugs \[[@B3]\], elevation of liver enzymes was sometimes accompanied by severe thrombocytopenia and other aggravated side effects \[[@B5], [@B6]\]. Current chemotherapeutic guidelines require stopping chemotherapy when hepatotoxicity, as indicated by AST and ALT levels, reaches four times the upper normal limit (\>100 U l^−1^) \[[@B7]\]. Studies noted that 56--90.5% of cancer patients had to cancel or delay chemotherapy due to serious complications \[[@B2], [@B3]\]. Changes in chemotherapy courses and drug doses reduced response rates to treatment from 68 to 30% \[[@B8]\].

Use of complementary and alternative medicine (CAM) among patients with cancer has become increasingly popular during the past few decades. A systematic review including 26 surveys of cancer patients from 13 countries showed that the prevalence of CAM use ranged from 7 to 64% \[[@B9]\]. In 2002, a survey of patients with breast, colon or prostate cancer found that 70.2% of respondents used CAM \[[@B10]\]. Traditional Chinese medicine (TCM) is popular among people with a Chinese background.

Taiwan has a two-tiered medical system, comprising both modern medicine and TCM. These two systems operate in parallel and the medical expenses of both are covered by the National Health Insurance system in Taiwan. Studies showed that 9--64% of patients with cancer used TCM in Taiwan \[[@B11]--[@B16]\]. According to recent statistics, 72 Western medical hospitals in Taiwan set up departments of TCM, which make it feasible to treat cancer with an integrative system of modern medicine and TCM \[[@B17]\]. While anecdotal evidence shows that TCM protects liver function, TCM used varied across studies and target groups were not confined to cancer patients. Reports of active management of liver injury related to chemotherapy are lacking in the literature \[[@B18], [@B19]\]. To the best of our knowledge, no study evaluated the effectiveness of TCM using objective indicators among patients with cancer receiving chemotherapy. The purpose of this study was 2-fold: to examine the effectiveness of TCM for protecting the liver from the toxic effects of chemotherapy and to determine if chemotherapy completion rates improved among patients with cancer receiving joint TCM and chemotherapy.

2. Methods {#sec2}
==========

We applied a case-control study design. Two senior oncology nurses used a structured questionnaire to independently abstract data from patients\' medical records. Inconsistent data were compared, and a consensus on questionable data was reached through discussion among the two data abstractors and the oncologists. Inconsistent data were uncommon and were mostly concerned with determining the timing of the data.

This study was a chart review study and involved no contact with the patients. After data abstraction completed, patient names were replaced by coded numbers to ensure anonymity. The study was approved by the human subjects committee at the study hospital (approval number CRC-08-09-03 issued in May 2009). Written consent was not required, since patient identifiers were not included in the data.

2.1. Participants {#sec2.1}
-----------------

All patients considered for the study had diagnoses of cancer, were older than 20 years of age, and were treated for cancer using chemotherapy in a teaching hospital in Taipei from January 2004 to December 2004. The study hospital offered both TCM and Western hemo-oncology services. Patients were referred by their oncologist or were self referred for TCM services. Thus, there was no gate-keeping system or formal referral criteria for medical treatment.

A total of 89 patients with cancer were identified from the medical records and their data were analyzed. Of the 89 patients, 37 (42%) ever received TCM prescribed by licensed TCM doctors, while 52 (58%) received modern medical treatments only. Among the 89 patients, 184 chemotherapy courses were identified. Of the 184 courses, 42 (23%) were given in conjunction with TCM (case group), and the remaining 142 (77%) courses without joint TCM served as the control group. Thus, the unit of analysis was one course of chemotherapy.

2.2. Treatment Protocols {#sec2.2}
------------------------

Patients had blood tests for AST and ALT before the start of a course of chemotherapy and once a week thereafter, according to hospital routine. Patients were advised to fast (nothing by mouth) for eight hours before the blood tests. The blood-testing instrument was calibrated daily by qualified technicians at the study hospital. The TCM medication used were Xiao-Chai-Hu-Tang, Huang-Lian-Jie-Du-Tang or Yin-Chen-Wu-Ling-San during chemotherapy, based on patient conditions as judged by TCM doctors. These TCM medications were traditional multi-component medications. According to TCM theory, these preparations strengthen liver function and detoxify the liver \[[@B20], [@B21]\] Botanical names for the components of the TCMs are presented in [Table 1](#tab1){ref-type="table"}. TCM medications used in this study were concentrated herbal extracts in the form of powders produced by a GMP-certified pharmaceutical company in Taiwan (Sun Ten Pharmaceutical Co., Ltd, Taichung, Taiwan). The TCM medications were prescribed for three times daily after meal. Each dosage comprised 5 g of TCM powder.

2.3. Measurements {#sec2.3}
-----------------

A structured four-part questionnaire was used to collect demographic data, including age, gender and disease history, such as hypertension, diabetes mellitus and hepatitis virus status. The second part collected disease and treatment data, including diagnosis, cancer stage, cancer status (newly diagnosed or recurrence), timing of chemotherapy (before or after surgery) and site of radiotherapy. The third part collected chemotherapeutic drugs and chemotherapy course data. Chemotherapeutic drugs which could cause damage to the liver cells of recipients were classified as having potential hepatotoxicity. Even chemotherapeutic drugs which were not classified as having hepatotoxicity could induce poor liver function among patients due to massive cell deaths resulting from chemotherapy and increased metabolic load associated with use of medicine. Therefore, we decided to include all courses of chemotherapy and treat potential hepatotoxicity of the chemotherapeutic drugs as a confounder in this study.

A chemotherapy course was regarded as complete when it was not stopped or postponed, based on recorded chemotherapy regimens. The fourth part collected liver function test data (AST and ALT) 1 week before chemotherapy, during chemotherapy (the last week of chemotherapy), and 2 weeks after chemotherapy.

2.4. Data Analysis {#sec2.4}
------------------

The Statistical Package for the Social Sciences (SPSS, version 11.0 for Windows, SPSS Inc, Chicago, IL) and Statistical Analysis System (SAS, version 8.2 SAS Institute, Cary, NC) were used to perform the data analyses. The characteristics of the study participants were summarized as the mean ± standard deviation (SD) for continuous variables and as proportions for categorical variables. Student\'s *t*-test and chi-square test were used, as appropriate, to analyze group differences. The generalized estimating equations (GEE) model was used to control the effect of study covariates and to analyze the independent effect of TCM therapy on liver function and completion of chemotherapy \[[@B22]\]. The GEE approach has been proposed as a non-parametric and appropriate method to conduct the repeated measurement analysis. This study applied GEE to account for correlated data resulting from repeated measurements across different time points and multiple observations (chemotherapy courses) of the same individual. In all analyses, a 5% significance level was used.

3. Results {#sec3}
==========

3.1. Subject Demographics {#sec3.1}
-------------------------

Of the 89 patient records studied, 63% were women, 24% had hypertension, 16% had diabetes mellitus, 8% carried hepatitis B virus and 3% carried hepatitis C virus. The age of the study participants raged from 28 to 88 years (mean 56.03, SD 12.75). Most of the patients had gastrointestinal cancer (40%) and breast cancer (30%). The cancer stages were stage IV (39%), stage III (36%), stage II (18%) and stage I (7%). The majority of patients were newly diagnosed with cancer (83%) ([Table 2](#tab2){ref-type="table"}). Characteristics of the courses of chemotherapy were compared by the case-control status ([Table 3](#tab3){ref-type="table"}). There were no significant differences between the case and control groups except for the cancer diagnosis and cancer stage. More controls had a diagnosis of breast cancer (45.2% versus 14.8%), while more cases had a cancer stage of III and IV (83.8% versus 61.9%). Chemotherapeutic drugs used in this study are listed in the end note to [Table 3](#tab3){ref-type="table"}. About 97% of all chemotherapy courses used chemotherapeutic drugs with potential hepatotoxicity. There were no significant differences between the case and control groups in terms of the use of chemotherapeutic drugs with potential hepatotoxicity.

3.2. AST Levels {#sec3.2}
---------------

Among the 184 chemotherapy courses (cases 42, controls 142), the mean AST did not differ significantly between the case and control groups 1 week before and 2 weeks after chemotherapy. However, the case group had significantly lower mean AST values during chemotherapy (24.12 versus 29.20, *P* = .01; [Table 4](#tab4){ref-type="table"}). Median AST values changed little and did not significantly differ between the case and control groups. Median AST values were 23 U l^−1^ for the cases at the three time points; while they were 23, 24 and 24 U l^−1^ for the controls 1 week before, during and 2 weeks after chemotherapy, respectively. The GEE results showed that the case group had significantly decreased AST values during chemotherapy relative to before chemotherapy than did the control group (**β**  = −6.90, *P* = .01). There was no significant difference in AST after chemotherapy relative to before chemotherapy between the case and control groups (**β**  = −3.45, *P* = .30). The main effect of time was significant in that during chemotherapy the participants had higher mean AST values than before chemotherapy (**β**  = 4.42, *P* \< .001); AST values before chemotherapy did not differ from those after chemotherapy (**β**  = 1.78, *P* = .11). The main effect of case-control status was not significant (**β**  = 2.48, *P* = .39). After adjusting for study covariates including age, gender, cancer stage, site of radiotherapy, cancer diagnosis and potential hepatotoxicity of the chemotherapeutic drugs, the study results remain quite similar that the significantly lower AST for the case group compared to the control group during chemotherapy was sustained (**β**  = −6.9, *P* = .01). AST values did not differ 2 weeks after chemotherapy between the case and control groups (**β**  = −3.48, *P* = .30). The significant effect of time (higher AST values during chemotherapy than before chemotherapy) was sustained (**β**  = 4.43, *P*\< .001) ([Table 5](#tab5){ref-type="table"}).

3.3. ALT Levels {#sec3.3}
---------------

Mean ALT did not differ significantly between the case and control groups at all three time points (1 week before, during and 2 weeks after chemotherapy). Nonetheless, the case group had lower mean ALT values during the chemotherapy with borderline significance (22.60 versus 26.33, *P* = .08; [Table 4](#tab4){ref-type="table"}). Median ALT values did not significantly differ between the case and control groups. Median ALT values were 20.5, 22.5 and 21.5 U l^−1^ for the case group, and 18, 19 and 19 U l^−1^ for the controls 1 week before, during and 2 weeks after chemotherapy, respectively. The GEE results showed that the case group had significantly decreased mean ALT values during chemotherapy relative to before chemotherapy than controls (**β**  = −5.99*, P* = .03). There was no significant difference in ALT after chemotherapy relative to before chemotherapy between the case and control groups (**β**  = −0.75, *P* = .83). The main effect of time was significant in that during chemotherapy the participants had higher mean ALT values than before chemotherapy (**β**  = 3.77, *P* = .01); ALT values before chemotherapy did not differ from those after chemotherapy (**β**  = 1.33, *P* = .38). The main effect of case-control status was not significant (**β**  = 0.44, *P* = .84). After adjusting for study covariates including age, sex, cancer stage, site of radiotherapy, cancer diagnosis, and potential hepatotoxicity of the chemotherapeutic drugs, the study results also remain similar that the significantly lower ALT for cases than controls during chemotherapy was sustained (**β**  = −5.95, *P* = .03). ALT values did not differ 2 weeks after chemotherapy between the case and control groups (**β**  = −0.75, *P* = .83). The significant effect of time (higher ALT values during chemotherapy than before chemotherapy) was sustained (**β**  = 3.77, *P* = .01) ([Table 6](#tab6){ref-type="table"}).

3.4. Chemotherapy Completion {#sec3.4}
----------------------------

The chemotherapy completion rate was 76% (32/42) for the case group and 59% (84/142) for the control group (*P* = .04). The GEE results showed that the case group tended to have higher odds of completing chemotherapy, but the results were not statistically significant \[odds ratio (OR) = 1.64, *P* = .16\]. Furthermore, after adjusting for age, sex, cancer stage, site of radiotherapy, cancer diagnosis, and potential hepatotoxicity of the chemotherapeutic drugs, there were no significant differences between the case and control groups for odds of completing one course of chemotherapy (OR = 1.59, *P* = .21).

4. Discussion {#sec4}
=============

We showed that TCM for patients with cancer receiving chemotherapy protected liver function during chemotherapy, as evidenced by lower blood AST and ALT levels, but the effect disappeared 2 weeks after chemotherapy. After adjustment for demographics and disease related factors, TCM lowered AST by 6.9 U l^−1^ (22.9%) and ALT by 5.95 U l^−1^ (19.7%) during chemotherapy. At 2 weeks after chemotherapy, the AST and ALT values returned to levels similar to the value 1 week before chemotherapy for the case group. For the control group, AST and ALT values significantly increased during chemotherapy then decreased to the level only slightly higher than the values before chemotherapy at 2 weeks after chemotherapy. A previous study showed that AST rose during chemotherapy then declined 3 days after chemotherapy \[[@B23]\]. The pattern was consistent with the trend among the controls in this study. The different pattern of AST- and ALT-value changes between the case and control groups in this study suggests efficacy of TCM for liver protection during chemotherapy.

The proposed scheme for the effect of TCM on liver protection is presented in [Figure 1](#fig1){ref-type="fig"}. During chemotherapy, the drugs stimulate liver and hepatic cells to detoxify and metabolize the chemotherapeutic drugs and this process can cause liver damage such as hepatitis and hepatic necrosis \[[@B24], [@B25]\]. When the liver is damaged, hepatic cells secrete AST and ALT, which can be detected in the serum. Thus, serum AST and ALT levels were used to assess the extent of damage to hepatic cells. Research shows that TCM decreased liver damage in the case of acute hepatitis through decreasing degeneration of hepatic cells and delaying or preventing liver fibrosis \[[@B26], [@B27]\]. In addition, TCM has antidotal properties that reduce superoxide anion activity \[[@B28]\]. In other words, TCM could prevent liver injury during chemotherapy through its antioxidant function and decreasing degeneration of liver cells or fibrosis. The other plausible explanations of the beneficial effect of TCM on liver function are hyperplasia of hepatic cells and formation of interferon. TCM preparations such as the rhizome of Chinese goldthread and umbellate pore fungus induce formation of interferon; the rhizome of Chinese goldthread also induces hyperplasia of hepatic cells \[[@B29], [@B30]\]. Hyperplasia of hepatic cells alleviates metabolic load and interferon treats hepatitis. Therefore, when patients with cancer receive chemotherapy, TCM preparations could stimulate the liver to proliferate and secrete interferon, activating liver self-defenses. At 2 weeks after chemotherapy, when no chemotherapeutic drugs were present to stimulate the hepatic cells, the effect of the TCM preparation disappeared. Determination of the mechanisms linking TCM preparations to improved liver function during chemotherapy were outside the scope of this study. Further studies are needed to examine the underlying mechanisms of TCM action.

While we found that the TCM preparations had no significant effect on completion of chemotherapy among patients with cancer, the patients who had TCM in conjunction with chemotherapy tended toward a higher rate of chemotherapy completion than those who had chemotherapy alone. There were many possible reasons why patients did not complete chemotherapy besides poor liver function and physical health. Reasons for cancellation and delay of chemotherapy were not available for analysis in the current study. More accurate measurement of this variable may yield different results. Further study is needed to examine whether TCM could increase chemotherapy completion rates.

There are a number of TCM preparations that are used to protect or improve liver function based on TCM theory. According to TCM theory, TCM preparations should be adjusted by adding or eliminating ingredients in order to agree with an individual\'s constitution. Therefore, the contents of TCM preparations vary based on patients\' conditions and TCM doctors\' recommendations. The TCM preparations used in this study were prescribed by licensed TCM doctors. Three multiple-herb preparations were used as the base, including Huang-Lian-Jie-Du-Tang, Yin-Chen-Wu-ling-san and Xiao-Chai-Hu-Tang. Other studies of TCM preparations showed improved liver function \[[@B29], [@B31]--[@B33]\]. The TCM preparations used in those studies had some overlap of herb components with those used in our current study. Nonetheless, there were still differences in herb components, thus, the comparability of results is limited.

4.1. Limitations {#sec4.1}
----------------

This case-control study used course of chemotherapy rather than individual patient as unit of analysis, and GEE was applied to account for the correlated data. This approach could enhance the comparability of the case and control courses and increase data efficiency, since different courses of the same individual could serve either as cases or controls depending on whether TCM was used. Despite these, the allotment of case and control status was based on patient\'s decisions to seek TCM treatment with or without an oncologist\'s referral. Therefore, there may be a concern for potential selection bias, but the use of objective rather than subjective indicators as the outcome variables and the use of statistical methods to adjust for confounders may mitigate this concern. This study included patients with different cancer diagnoses and on different chemotherapeutic drugs. Due to the small number of patients in this study, subgroup analysis could not be performed. Nonetheless, the significant effects of lowered AST and ALT were sustained given that the GEE approach was used to account for correlated observations and adjustment for potential confounders in the study. A future study with more-homogeneous samples and a larger sample size is needed. Potential interactions between TCMs and chemotherapeutic drugs should be examined in future studies. There is a lack of information on other indicators for liver function such as GGT, bilirubin and ALD in this study. This study only examined a limited spectrum of patient outcomes; in addition to a more-complete liver profile, information about the treatment efficacy such as tumor reduction, relapse and blood profile should be considered in future studies.

5. Conclusion {#sec5}
=============

Integrative care for cancer patients using modern medicine and TCM is an emerging trend. We demonstrated that use of TCM preparations improved liver function during chemotherapy among our patients with cancer receiving chemotherapy. Randomized controlled trails are warranted in order to confirm the effectiveness of various TCM preparations for protection of liver function among cancer patients receiving chemotherapy.

The fee for the English proofreading of the manuscript was provided by the Committee on Chinese Medicine and Pharmacy, Department of Health, Taiwan (CCMP98- RD-034).
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###### 

Botanical names for the components of TCMs.

  TCM medication                                                       
  -------------------------------- ----------------------------------- ---------------------------------
  Buplerum chinense DC.            The rhizome of Chinese goldthread   Poria cocos tuckahoe
  Pinellia ternate                 Scutellaria baicalensis Georgi      Agaric umbellate pore fungus
  Ginseng                          Phellodendri Cortex                 Largehead atractylodes Rh
  Scutellaria baicalensis Georgi   Gardeniae Fructus                   Cassia twigs, ramulus cinnamomi
  Glycyrrhizae Radix                                                   Alismatis rhizoma
  Ginger                                                               Artemisiae scopariae herba
  Big jujube                                                           

###### 

Characteristics of the study participants (*N* = 89).

                                                 *n*   Percentage (%)
  ---------------------------------------------- ----- ----------------
  Age (years)                                          
   28--40                                        8     9.0
   41--50                                        26    29.2
   51--60                                        23    25.8
   61--70                                        20    22.5
   71--80                                        10    12.4
   80--88                                        2     1.1
  Sex                                                  
   Male                                          33    37.1
   Female                                        56    62.9
  Cancer diagnosis                                     
   Breast cancer                                 27    30.3
   Gastrointestinal cancer                       36    40.4
   Lung cancer                                   7     7.9
   Lip, oral cavity, pharynx and throat cancer   5     5.6
   Genital and urological cancer                 4     4.5
   Lymph and blood system cancer                 7     7.9
   Bone and connective tissue cancer             2     2.2
  Cancer stages                                        
   I                                             6     6.7
   II                                            16    18.0
   III                                           32    36.0
   IV                                            35    39.3
  Cancer status                                        
   Newly diagnosed                               74    83.1
   Relapse                                       15    16.9
  Hepatitis virus carrier                              
   B                                             7     7.9
   C                                             3     3.4

###### 

Characteristics by the case-control status (*N* = 184).

                                                 Case (*n* = 42)            Control (*n* = 142)        *t*/*χ* ^2^   *P*
  ---------------------------------------------- -------------------------- -------------------------- ------------- ---------
  Age                                            Mean = 58.43; SD = 12.28   Mean = 55.17; SD = 10.12   1.57          .12
  Sex                                                                                                  2.28          .09
   Male                                          14 (33.3%)                 66 (46.5%)                               
   Female                                        28 (66.7%)                 76 (53.5%)                               
  Cancer diagnosis                                                                                     43.47         \<.0001
   Breast cancer                                 21 (14.8%)                 19 (45.2%)                               
   Gastrointestinal cancer                       88 (62.0%)                 8 (19.0%)                                
   Lung cancer                                   15 (10.6%)                 2 (4.8%)                                 
   Lip, oral cavity, pharynx and throat cancer   2 (1.4%)                   4 (9.5%)                                 
   Genital and urological cancer                 7 (4.9%)                   3 (7.1%)                                 
   Lymph and blood system cancer                 9 (6.3%)                   3 (7.1%)                                 
   Bone and connective tissue cancer             0 (0.0%)                   1 (2.4%)                                 
   Others                                        0 (0.0%)                   2 (4.8%)                                 
  Cancer stages                                                                                        19.15         \<.001
   I                                             2 (1.4%)                   7 (16.7%)                                
   II                                            21 (14.8%)                 9 (21.4%)                                
   III                                           51 (35.9%)                 14 (33.3%)                               
   IV                                            68 (47.9%)                 12 (28.6%)                               
  Site of radiotherapy                                                                                 5.11          .08
   No                                            58 (40.8%)                 23 (54.8%)                               
   Abdomen                                       45 (31.7%)                 6 (14.3%)                                
   Non-abdomen                                   39 (27.5%)                 13 (31.0%)                               
  Hepatotoxicity of the chemotherapeutic drugs                                                         0.13          .72
   Yes                                           41 (97.6%)                 137 (96.5%)                              
   No                                            1 (2.4%)                   5 (3.5%)                                 

*t* and *χ* ^2^ are respective statistical values from Student\'s; *t*-test and chi-squared test; the *P-*value is the probability assuming that null hypothesis is true (two-tailed test); the significance level was set to *P* \< .05. The chemotherapeutic drugs used in this study were Ara-C, bleomycin, carboplatin, cisplatin, cyclophosphamide, dacarbazine, doxorubicin, etoposide, fluorouracil, formoxol, gemcitabine, ifosfamide, mitoxantrone, methotrexate, mitomycin C, oxaliplatin, taxol and taxotere (with potential hepatotoxicity); arimidex, CPT-11, faslodex, herceptin, navelbine, tamoxifen, UFUR and vinblastine (without hepatotoxicity).

###### 

Mean AST and ALT values by case-control status.

                            Case (*n* = 42)   Control (*n* = 142)   *t*     *P*             
  ------------------------- ----------------- --------------------- ------- ------- ------- -----
  AST before chemotherapy   26.55             16.04                 24.76   10.09   −0.82   .41
  AST during chemotherapy   24.12             5.37                  29.20   20.07   2.61    .01
  AST after chemotherapy    25.49             7.73                  26.67   14.32   0.50    .61
  ALT before chemotherapy   24.17             15.34                 22.70   15.65   −0.53   .59
  ALT during chemotherapy   22.60             6.97                  26.33   20.90   1.76    .08
  ALT after chemotherapy    24.74             15.88                 24.35   17.08   −0.13   .89

*t* is the statistical value from Student\'s; *t*-test; the *P*-value is the probability assuming that the null hypothesis is true (two-tailed test); the significance level was set to *P* \< .05.

###### 

Crude and net effect of TCM use on AST.

                         Estimate   95% CI   Z       *P*     
  ---------------------- ---------- -------- ------- ------- --------
  Crude effect                                               
   TCM cases             2.48       −3.21    8.19    0.85    .39
   During chemotherapy   4.42       2.01     6.82    3.60    \<.001
   After chemotherapy    1.78       −0.46    4.04    1.56    .11
   Case × During         −6.90      −12.30   −1.50   −2.51   .01
   Case × After          −3.45      −10.08   3.17    −1.02   .30
  Net effect                                                 
   TCM cases             3.61       −2.47    9.70    1.16    .24
   During chemotherapy   4.43       2.01     6.85    3.59    .0003
   After chemotherapy    1.81       −0.44    4.05    1.60    .11
   Case × During         −6.9       −12.30   −1.50   −2.51   .01
   Case × After          −3.48      −10.08   3.11    −1.03   .30

The reference groups were controls for case--control status and before chemotherapy for time.

Crude effect was unadjusted results. Net effect was results adjusted for age, sex, cancer stage, site of radiotherapy, cancer diagnosis and potential hepatotoxicity of the chemotherapeutic drugs.

*Z* is the statistical value from GEE; the *P* value is the probability assuming that the null hypothesis is true (two-tailed test); the significance level was set to *P* \< .05; "×\" indicates an interaction.

###### 

Crude and net effect of TCM use on ALT.

                         Estimate   95% CI   Z       *P*     
  ---------------------- ---------- -------- ------- ------- ------
  Crude effect                                               
   TCM cases             0.44       −3.99    4.88    0.20    0.84
   During chemotherapy   3.77       0.68     6.86    2.39    0.01
   After chemotherapy    1.33       −1.68    4.34    0.87    0.38
   Case × During         −5.99      −11.50   −0.47   −2.13   0.03
   Case × After          −0.75      −7.81    6.29    −0.21   0.83
  Net effect                                                 
   TCM cases             −0.33      −5.47    4.81    −0.13   0.89
   During chemotherapy   3.77       0.68     6.87    2.39    0.01
   After chemotherapy    1.33       −1.68    4.34    0.87    0.38
   Case × During         −5.95      −11.47   −0.44   −2.12   0.03
   Case × After          −0.75      −7.79    −6.27   −0.21   0.83

The reference groups were controls for case-control status and before chemotherapy for time.

Crude effect was unadjusted results. Net effect was results adjusted for age, sex, cancer stage, site of radiotherapy, cancer diagnosis, and potential hepatotoxicity of the chemotherapeutic drugs.

*Z* is the statistical value from the GEE; the *P* value is the probability assuming that the null hypothesis is true (two-tailed test); the significance level was set to *P* \< .05; " ×\" indicates an interaction.
